Acelyrin, Inc. (SLRN) Stock Analysis
DELISTED 2025
What happened to Acelyrin, Inc. (SLRN) stock?
Acelyrin, Inc. (SLRN) no longer trades on public markets. It was delisted in May 2025. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- May 2025
- Last recorded price (historical):
- $2.27 (last quote on record before the May 2025 delisting; historical, not a current quote)
Market cap $229M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Acelyrin, Inc. (SLRN). Acelyrin, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative medicines. Their lead product candidate, izokibep, is undergoing Phase 3 and Phase 2 clinical trials for various inflammatory diseases.
Last analyzed: Mar 16, 2026Dated analysis: the newest financial statements on file are 25 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
Acelyrin, Inc. (SLRN) Healthcare & Pipeline Overview
More about this archive record
Can I still buy SLRN shares?
No. SLRN stopped trading on public markets in May 2025, so the shares are not available through a broker. Anything you see quoted for SLRN elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SLRN stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Acelyrin, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.